Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
127.74
+0.62 (0.49%)
At close: Nov 12, 2024, 4:00 PM
129.01
+1.27 (0.99%)
Pre-market: Nov 13, 2024, 4:13 AM EST
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,800 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
2,800
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,425,969
Profits / Employee
$165,414
Market Cap
7.72B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,800 | 0 | - |
Dec 31, 2022 | 2,800 | -400 | -12.50% |
Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
Dec 31, 2020 | 1,940 | 320 | 19.75% |
Dec 31, 2019 | 1,620 | 260 | 19.12% |
Dec 31, 2018 | 1,360 | 150 | 12.40% |
Dec 31, 2017 | 1,210 | 170 | 16.35% |
Dec 31, 2016 | 1,040 | 130 | 14.29% |
Dec 31, 2015 | 910 | 40 | 4.60% |
Dec 31, 2014 | 870 | 60 | 7.41% |
Dec 31, 2013 | 810 | 200 | 32.79% |
Dec 31, 2012 | 610 | 179 | 41.53% |
Dec 31, 2011 | 431 | 189 | 78.10% |
Dec 31, 2010 | 242 | 14 | 6.14% |
Dec 31, 2009 | 228 | 12 | 5.56% |
Dec 31, 2008 | 216 | -193 | -47.19% |
Dec 31, 2007 | 409 | 224 | 121.08% |
Dec 31, 2007 | 185 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Grifols | 23,737 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
Legend Biotech | 1,826 |
Glaukos | 907 |
Ascendis Pharma | 879 |
Cytokinetics | 423 |
Madrigal Pharmaceuticals | 376 |
JAZZ News
- 6 days ago - Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth? - Benzinga
- 6 days ago - Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results - PRNewsWire
- 12 days ago - Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia - PRNewsWire
- 20 days ago - Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024 - PRNewsWire
- 27 days ago - Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook - Seeking Alpha
- 4 weeks ago - Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer - Benzinga
- 4 weeks ago - Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - PRNewsWire